Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma by Wilken, Reason et al.
REVIEW Open Access
Curcumin: A review of anti-cancer properties and
therapeutic activity in head and neck squamous
cell carcinoma
Reason Wilken
1, Mysore S Veena
1,3, Marilene B Wang
1,2, Eri S Srivatsan
1,3*
Abstract
Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa plant, commonly known as
turmeric. Curcumin has been used extensively in Ayurvedic medicine for centuries, as it is nontoxic and has a
variety of therapeutic properties including anti-oxidant, analgesic, anti-inflammatory and antiseptic activity. More
recently curcumin has been found to possess anti-cancer activities via its effect on a variety of biological pathways
involved in mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis and metastasis.
Curcumin has shown anti-proliferative effect in multiple cancers, and is an inhibitor of the transcription factor NF-
B and downstream gene products (including c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-a, interleukins and MMP-9).
In addition, curcumin affects a variety of growth factor receptors and cell adhesion molecules involved in tumor
growth, angiogenesis and metastasis. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common
cancer worldwide and treatment protocols include disfiguring surgery, platinum-based chemotherapy and
radiation, all of which may result in tremendous patient morbidity. As a result, there is significant interest in
developing adjuvant chemotherapies to augment currently available treatment protocols, which may allow
decreased side effects and toxicity without compromising therapeutic efficacy. Curcumin is one such potential
candidate, and this review presents an overview of the current in vitro and in vivo data supporting its therapeutic
activity in head and neck cancer as well as some of the challenges concerning its development as an adjuvant
chemotherapeutic agent.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common form of cancer worldwide and
represents approximately 5% of all cancers diagnosed
annually in the United States [1,2]. Every year more
than 30,000 cases of oral and pharyngeal cancer are
diagnosed, and over 8,000 individuals die of the disease.
If the definition of HNSCC is expanded to include lar-
yngeal cancers, the number of annually diagnosed cases
grows to over 42,000 individuals and results in over
12,000 deaths per year in the United States [3].
The development of head and neck malignancies is
strongly associated with certain risk factors such as
tobacco use, alcohol consumption and environmental
exposures (such as EBV infection in the case of
nasopharyngeal carcinoma). Additionally, human papil-
loma virus (HPV) infection is emerging as a causative
agent for HNSCC and may account for the increased
incidence of this malignancy in patients who do not
have histories of alcohol or tobacco usage [4]. By virtue
of their inconspicuous location, many cases of HNSCC
are not discovered until the cancer is at a later stage,
not uncommonly until after spread to lymph nodes in
the neck. A growing tumor in the head and neck region
may not cause any discernable symptoms and a large
portion of earlier-stage oral tumors are discovered inci-
dentally, often by dental providers.
Standard treatment regimens for head and neck can-
cer depend on the stage of the disease. Early stage (stage
I and II) tumors are treated primarily with surgery or
radiotherapy, with both modalities resulting in similar
local control and survival rates. Radiation may also be
used postoperatively when surgical margins are close or
positive, or if perineural or lymphovascular invasion by
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cers often require multi-modality therapy with surgery,
radiation and chemotherapy which can result in very
high morbidity [5]. Concurrent chemoradiation (CRT)
for locoregionally advanced HNSCC is the preferred
treatment in cases of unresectable disease or instances
when surgical resection would result in an unacceptable
functional loss for the patient. Recent years have seen a
trend towards organ-sparing therapies of chemotherapy
and radiation for resectable cancers of the oropharynx,
hypopharynx and larynx [6].
Platinum-based agents form the backbone of the stan-
dard chemotherapeutic regimens for head and neck can-
cer. Cisplatin (cis-diamminedichloroplatinum) is a
widely used drug in the class of platinum-based che-
motherapies (which also includes carboplatin & oxalipla-
tin). The platinum compounds work by the formation of
DNA crosslinks within cells, leading to apoptosis and
cellular senescence. The efficacy of cisplatin in HNSCC
is greatly increased when combined with other che-
motherapeutic agents, such as taxanes (paclitaxel and
docetaxel) and 5-fluorouracil (5-FU) (Table 1) [7-10].
The potential adverse effects from the treatment for
HNSCC are numerous. Radical surgery can result in dis-
figurement & functional impairment, but even the
organ-preserving treatment methods of radiation and
chemotherapy may result in a host of negative side
effects, some permanent [11]. Common side effects of
radiotherapy include mucositis, oral candidiasis, loss of
taste and xerostomia, which may be permanent due to
the damaging effect of radiation on the salivary glands
[11]. Osteoradionecrosis of bones within the radiation
field (most commonly the mandible) may occur as a
result of damage to the bone vasculature and osteocytes
and is one of the most serious complications of radio-
therapy [12]. The toxic effects of platinum-based
chemotherapy are dose dependent and include renal,
otologic, and bone marrow suppressive sequelae
(Table 1) [7-10].
Despite continuing research and advances in treat-
ment, the clinical outcomes and overall survival rates
for HNSCC have not improved significantly over the
last several decades, with the overall 5 year survival rate
as low as 50% [1,2,13]. As a result, there has been conti-
nuing investigation into potential alternative and less
toxic therapies for head and neck cancer, with the aim
of achieving a more favorable clinical outcome while
reducing treatment morbidity. The class of molecularly
targeted therapies against the epidermal growth factor
receptor (EGFR) is one such example, as EGFR is over-
expressed in a number of head and neck cancers. Cetux-
imab is an anti-EGFR monoclonal antibody that was
approved by the Food and Drug Administration in 2004
for the treatment of advanced colon cancer. In 2006,
Cetuximab was approved for use in head and neck squa-
mous cell carcinoma—both in combination with radio-
therapy for advanced HNSCC as well as single-agent
therapy for platinum-refractory head and neck cancer
(Table 1). Several studies of cetuximab as an adjuvant
agent with radiotherapy have demonstrated improved
locoregional control and statistically significant increases
in both progression-free and overall survival [14,15].
Table 1 Current chemotherapeutic models in head and neck cancer
Agent Mechanism Mode of Usage in HNSCC Significant Adverse Effects Reference
Platinum
agents
(Cisplatin/
Carboplatin)
Formation of DNA
adducts, induction of
apoptosis and
senescence
Cisplatin/Carboplatin single-agent Cisplatin/
Carboplatin in combination with 5-Flurouracil
Nephrotoxicity (acute renal
failure, chronic renal insufficiency)
Ototoxicity (high-frequency hearing loss)
Neurotoxicity (peripheral neuropathy)
Hematologic (myelosupression)
Gastrointestinal (nausea, vomiting)
Electrolyte disturbances
(hypomagnesiumia/hypokalemia/
hypocalcemia)
[8-12]
5-Flurouracil Anti-metabolite
(pyrimidine analog,
inhibits thymidylate
synthase)
5-Flurouracil in combination with Cisplatin/
Carboplatin, and with or without Paclitaxel
Cardiac toxicity (angina, myocardial ischemia),
Gastrointestinal (nausea, omiting, ulcers),
Hematologic (myelosupression),
Thrombophlebitis, Dermatologic (rash)
[8-10]
Taxanes
(Paclitaxel/
Docetaxel)
Anti-microtubular
agent
(inhibitor of mitosis)
Paclitaxel in combination with Carboplatin/
Cisplatin, and with or without 5-Fluoruracil
Cardiovascular (hypotension, EKG changes)
Gastrointestinal (mucositis, nausea, vomiting)
Hematologic (neutropenia, leukopenia,
thrombocytopenia), Neuromuscular (peripheral
neuropathy, myalgias), Hepatic (elevated liver
enzymes)
[9,10]
Cetuximab Anti-EGFR
monoclonal antibody
Cetuximab plus radiation therapy Single-agent
cetuximab in platinum refractory HNSCC Phase
I/II trial of cetuximab plus 5-FU and platinum
agents (on going)
Infusion reaction Dermatologic (acneform rash,
pruritis)
Gastrointestinal (abdominal pain, constipation,
diarrhea, nausea, vomiting), Respiratory
(dyspnea, cough), Neuromuscular weakness
[14-17,202]
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chemotherapy in platinum-resistant recurrent or meta-
static head and neck cancer has also been studied and
demonstrated increased treatment efficacy and improved
overall survival without a significant increase in toxicity
[16,17].
Curcumin, an Indian spice with antioxidant, anti-
inflammatory and anti-cancer properties, has shown
promise both as a potential chemopreventive agent as
well as a novel adjuvant treatment for head and neck
malignancies. This review will discuss the biological
properties of curcumin, with emphasis on the molecular
pathways modulated by the spice that may prove useful
in the treatment of head and neck squamous cell
carcinoma.
Curcumin
Curcumin (diferuloylmethane) is the chief component of
the spice turmeric and is derived from the rhizome of the
East Indian plant Curcuma longa. Curcuma longa is a
member of the Zingiberacae (ginger) family of botanicals
and is a perennial plant that is native to Southeast Asia
[18]. Turmeric contains a class of compounds known as
the curcuminoids, comprised of curcumin, demethoxy-
curcumin and bisdemethoxycurcumin (Figure 1) [19].
Curcumin is the principal curcuminoid and comprises
approximately 2-5% of turmeric; it is responsible for the
yellow color of the spice as well as the majority of tur-
meric’s therapeutic effects [18]. Aside from being
employed as a flavoring and coloring agent in food,
turmeric has also been widely used in Ayurvedic medi-
cine for its anti-oxidant, antiseptic, analgesic, antimalarial
and anti-inflammatory properties [20]. Curcumin has
been consumed as a dietary supplement for centuries and
is considered pharmacologically safe [21].
Antioxidant Activity
Curcumin is a lipophilic polyphenol and thus is insolu-
ble in water, but is readily soluble in organic solvents
such as dimethylsulfoxide, acetone and ethanol [20,22].
The antioxidant activity of the curcuminoids comes by
virtue of their chemical structure. The curcuminoids
consist of two methoxylated phenols connected by two
a, B unsaturated carbonyl groups that exist in a stable
enol form [23]. Curcumin has been shown to inhibit
lipid peroxidation using linoleate, a polyunsaturated
fatty acid that is able to be oxidized and form a fatty
acid radical. It has been demonstrated that curcumin
acts as a chain-breaking antioxidant at the 3’ position,
resulting in an intramolecular Diels-Alder reaction and
neutralization of the lipid radicals [24]. In addition to
inhibiting lipid peroxidation, curcumin demonstrates
free radical-scavenging activity. It has been shown to
scavenge various reactive oxygen species produced by
macrophages (including superoxide anions, hydrogen
peroxide and nitrite radicals) both in vitro as well as in
vivo using rat peritoneal macrophages as a model
[25,26]. Inducible nitric oxide synthase (iNOS) is an
enzyme found in macrophages that generates large
amounts of NO to provide the ‘oxidative burst’ neces-
sary for defense against pathogens. iNOS is induced in
response to an oxidative environment, and the NO gen-
erated can react with superoxide radicals to form perox-
ynitrite, which is highly toxic to cells. It has been shown
that curcumin downregulates the iNOS activity in
macrophages, thus reducing the amount of reactive oxy-
gen species (ROS) generated in response to oxidative
stress [27,28]. Additional studies in microglial cells
(brain macrophage analogs) demonstrated reduced NO
generation and protection of neural cells from oxidative
stress following curcumin treatment, thus the spice and
may be useful in reducing the neuroinflammation asso-
ciated with degenerative conditions such as Alzheimer’s
disease [29-31].
Anti-inflammatory Activity: Effect on NF-B Pathway
Curcumin has been shown to suppress the activation of
NF-B, an inducible transcription factor that regulates
the expression of a host of genes involved in inflamma-
tion, cellular proliferation and cell survival [32-57].
Genes regulated by NF-B include cyclooxygenase-2
(COX-2), IBa,T N F - a, cyclin D1, ICAM-1, c-myc, Bcl-
2, MMP-9, inducible nitric oxide synthase (iNOS), and
interleukins including IL-6 and IL-8 [19,35,36,58,59].
Figure 1 Structure of the curcuminoids curcumin,
demethoxycurcumin and bisdemethoxycurcumin.
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stressful stimuli such as cytokines, UV irradiation, free
radicals, hypoxia (including cigarette smoke) and infec-
tious antigens [60-64]. Activation of NF-B is increased
in many cancers, and is associated with various steps in
the development of malignancy such as expression of
anti-apoptotic genes, angiogenesis, tumor promotion
and metastasis [65]. Studies from our laboratory as well
as others have demonstrated constitutive expression of
NF-B in head and neck squamous cell carcinoma
[45,48,53,66,67].
NF-B is a heterodimeric protein composed of five
subunits: RelA (p65), RelB, c-Rel, NF-B1 (p50 and
p105) and NF-B2 (p52) [68]. The complex is retained
in the cytoplasm in an inactive form by IB (inhibitor of
NF-B), which is composed of a and b subunits. Upon
receipt of the appropriate chemical signals that initiate
NF-B activation, several steps are required to free NF-
B from this inhibitory binding. IB must be phosphoy-
lated at it’s a subunit by IK (inhibitor kappa B kinase)
which results in ubiquitination and degredation of the
phosphorylated IBa and the release of NF-Bf r o mi t s
stationary location in the cytoplasm. The unbound NF-
B is then available for transport into the nucleus where
it may bind to DNA and activate transcription.
Curcumin’s inhibitory effect on the NF-Bp a t h w a yi s
central to providing the compound with its anti-inflam-
matory properties. Curcumin blocks the IK-mediated
phosphorylation and degredation of IBa,t h u sN F - B
remains bound to IBa in the cytoplasm and is not able
to enter the nucleus to activate transcription [34,35,53].
Studies involving suppression of NF-B activity have
demonstrated a subsequent down-regulation of COX-2
a n di N O Sa n dd e c r e a s e dp r o d u c t i o no fi n f l a m m a t o r y
markers [33,36,41]. Consistent with its effect on NF-B,
curcumin has been shown to inhibit the production of
inflammatory cytokines by activated monocytes and
macrophages, including COX-2, liopxygenase (LOX),
iNOS, monocyte chemotactic protein-1 (MCP-1), mono-
cyte inflammatory protein-1 (MIP-1a) and interleukins
including IL-1, -2, -6, -8, and -12 [69,70].
In addition to inhibiting NF-B activation, curcumin
also has suppressive effects on other pathways involved
in inflammation. The arachadonic acid pathway for eico-
sanoid biosynthesis is an important participant in the
inflammatory response, generating a host of reactive
lipid products including leukotrienes, prostaglandins,
prostacyclins and thromboxanes. Curcumin has been
shown to decrease the metabolism of arachadonic acid
by downregulating the activity of LOX and COX-2, both
at the transcriptional level as well as via post-transla-
tional enzyme inhibition [70-72]. More recently, it has
been demonstrated that curcumin inhibits prostaglandin
E2 biosynthesis through direct inhibition of the
microsomal prostaglandin E2 synthase-1 enzyme [73]. In
addition, the free-radical scavenging activity of curcumin
also contributes to its anti-inflammatory properties by
decreasing the amount of oxidative stress that can trig-
ger the inflammatory cascade. The anti-inflammatory
properties of curcumin have been investigated in a num-
ber of disease entities such as Alzheimer’s disease, cardi-
ovascular disease, diabetes, asthma, inflammatory bowel
disease, arthritis, pancreatitis and renal disease [74-90].
Anti-cancer Activity: Suppression of Carcinogenesis
Curcumin has been studied in multiple human carcinomas
including melanoma, head and neck, breast, colon, pan-
creatic, prostate and ovarian cancers [45,48,53,91-96]. Epi-
demiological studies attribute the low incidence of colon
cancer in India to the chemopreventive and antioxidant
properties of diets rich in curcumin [97]. The mechanisms
by which curcumin exerts its anti-cancer effects are com-
prehensive and diverse, targeting many levels of regulation
in the processes of cellular growth and apoptosis. Besides
the vertical effects of curcumin on various transcription
factors, oncogenes and signaling proteins, it also acts at
various temporal stages of carcinogenesis——from the
initial insults leading to DNA mutations through the pro-
cess of tumorigenesis, growth and metastasis (Figure 2).
Because of the far-reaching effects and multiple targets of
curcumin on the cell growth regulatory processes, it holds
much promise as a potential chemotherapeutic agent for
many human cancers.
Curcumin’s potent anti-oxidant and free-radical
quenching properties play an important role in the inhi-
bitory effects of the compound on the initial stages of
carcinogenesis. It has been shown that curcumin has the
ability to suppress UV irradiation-induced DNA muta-
genesis and induction of cellular SOS functions [98]. In
addition to the inhibitory effects on the production of
nitric oxide (NO) and the ability to scavenge DNA-
damaging superoxide radicals, curcumin also affects
b o t ht h eP h a s eIa n dP h a s eI Ie n z y m e so ft h eh e p a t i c
cytochrome p450 enzyme system involved in the oxida-
tion and detoxification of toxic substances. Curcumin
has been shown to inhibit the Phase I enzymes (includ-
ing cytochrome p450 isoforms and p450 reductase)
which are induced in response to toxin exposure and
create a host of carcinogenic metabolites that contribute
to DNA adduct formation during the oxidation of such
substances [99]. Conversely, curcumin induces the
Phase II enzymes involved in detoxification of toxic
metabolites (including glutathione S-transferase, glu-
tathione peroxidase and glutathione reductase) [100].
Curcumin’s inhibitory effect on carcinogenesis has been
demonstrated in several animal models of various tumor
types including oral cancer, mammary carcinoma and
intestinal tumors [101-103].
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NF-B and AP-1 are two transcription factors intimately
involved in the cellular pathways leading to tumorigen-
esis. As discussed earlier, NF-B expression is induced
by various stressful stimuli (including oxidative stress,
cytokines such as TNF-a and IL-1, UV irradiation and
infectious antigens) and results in expression of genes
involved in inflammation and cellular proliferation. AP-
1 is a transcription factor composed of dimers or het-
erodimers from the Jun, Fos, and ATF families of pro-
teins that binds at a specific DNA site known as TPA-
responsive elements (TREs) containing the consensus
sequence 5’-TGAG/CTCA-3’ [104]. AP-1 is also acti-
vated in response to tumor promoters, pro-inflamma-
tory cytokines, UV irradiation and oxidative stress, and
the activation of both transcription factors was shown
to be required for maintaining transformed tumorigenic
phenotypes in mouse epidermal JB6 cells [105]. Like
NF-B, AP-1 regulates the expression of a variety of
genes involved in control of the cell cycle and apoptosis.
The c-Jun domain of AP-1 is a positive regulator of
cyclin D1 expression, contributing to the induction of a
tumorigenic phenotype. c-Jun is also a negative regula-
tor of p53 expression and fibroblast cells expressing
constitutive levels of c-Jun express lower levels of both
p53 and the p53-regulated cyclin-dependant kinase inhi-
bitor p21
Cip1/Waf1 and fail to undergo growth arrest fol-
lowing UV exposure [106]. In addition, c-Jun has been
shown to down-regulate the expression of p16 and
antagonize JunB mediated p16 activation [107].
Curcumin has an inhibitory effect on both NF-B and
AP-1 activation. As reviewed above, curcumin’se f f e c t
on NF-B is mediated through inhibition of IKa n d
results in inactive NF-B remaining bound to IBa in
the cytoplasm. As a result, curcumin has been shown to
suppress the expression of a variety of NF-B regulated
Figure 2 Overview of the anti-cancer effects of curcumin. Curcumin suppresses the activation of NF-B via inhibition of IKB activity, leading
to suppression of many NF-B-regulated genes involved in tumorigenesis including TNF,COX-2, cyclin D1, c-myc, MMP-9 and interleukins.
Curcumin is involved in cell cycle control and stimulation of apoptosis via upregulation of p16 and p53. In addition, curcumin is a modulator of
autophagy and has inhibitory effects on tumor angiogenesis and metastasis via suppression of a variety of growth factors including VEGF, COX-2,
MMPs and ICAMs.
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growth including cyclin D1, VEGF, COX-2, c-myc, Bcl-
2, ICAM-1 and MMP-9 [108,109]. In the case of AP-1,
curcumin has been shown to downregulate the produc-
tion of c-jun mRNA in vivo. Thus, it is proposed that
decreased production of the Jun-Fos complex is the
underlying mechanism for the decreased AP-1 transcrip-
tional activity in the presence of curcumin and unlike
with other inhibitors of Ap-1, this effect is independent
of the redox status of the cell [110].
Effect on Cell Cycle Regulation and Apoptosis
Cellular growth and proliferation is a highly regulated
event in normal cells, and derangements of the cell
cycle can lead to uncontrolled proliferation and contri-
bute to the malignant phenotype of tumor cells. The
mammalian cell cycle consists of four main stages: G1,
S, G2 and M, with G1 and G2 being referred to as “gap”
phases between the events of DNA synthesis and mito-
sis, respectively (Figure 3) [111]. In addition, there is a
fifth phase, referred to as G0 which represents a state of
quiescence outside the cell cycle in which cells are not
actively dividing or preparing to divide. Control of the
cell cycle is accomplished via the coordinated interac-
tion of cyclins with their respective cyclin-dependant
kinases (CDKs) to form active complexes and drive cells
into the next phase at the appropriate time. Regulatory
checkpoint control is mediated by the tumor suppressor
gene p53 and serves to monitor the accuracy of vital
events such as DNA replication and chromosome
segregation, and can result in halting of the cell cycle to
allow for repair if delinquencies are detected [112].
Specific cyclin/CDK complexes regulate various points
in the cycle and are themselves substrates for other reg-
ulatory molecules with the most regulated points being
the G1/S and G2/M transitions. Cyclin D family of pro-
teins complex with CDK4 and CDK6 and promote pro-
gression through G1, Cyclin E/CDK2 complex promotes
entry into S phase, Cyclin A/CDK2 stimulates G2 pro-
gression, and Cyclin B/CDK1 activates entry into the
mitotic phase [113].
There are two distinct families of CDK inhibitors: the
INK-4 family (p15
Ink4b,p 1 6
Ink4a,p 1 8
Ink4c,p 1 9
Ink4d)
a n dt h eC i p / K i pf a m i l y( p 2 1
Cip1/Waf1,p 2 7
Kip1,p 5 7
Kip2) .T h eI N K 4f a m i l yo fi n h i b i t o r sb i n d st oC D K 4a n d
CDK 6 to prevent their association with Cyclin D, while
the Cip/Kip family binds both CDKs and cyclins to inhi-
bit the formation of the various cyclin/CDK complexes
[114,115]. At the G1/S transition, the Cyclin D/CDK4,6
complexes promote progression by phosphorylating the
pRB protein, releasing the transcription factor E2F and
freeing it to transcribe genes required for cell division
[116,117]. Curcumin has been shown to upregulate the
expression of the Cip/Kip family of CDK inhibitors (p21
Cip1/Waf1 and p27
Kip1), thus inhibiting the association of
cyclin D1 with CDK4,6 [118]. In addition, decreased
phosphorylation of Rb and suppressed transcription of
E2F-regulated genes in thep r e s e n c eo fc u r c u m i nh a s
been demonstrated [119].
Derangements in the regulatory control of the cell cycle
c a nr e s u l ti nt h ef o r m a t i o no ft u m o rc e l l s ,i nw h i c h
growth and proliferation proceeds unchecked. One such
example is overexpression of cyclin D1, which has been
observed in many types of cancer including hematologic
malignancies and various solid tumors [120,121]. Curcu-
min has been shown to suppress the expression of cyclin
D1 in many types of cancer including head and neck,
colon, bladder, breast, cervical and pancreatic carcino-
mas, an effect attributed to curcumin’s inhibition of NF-
B activation and subsequent suppression of downstream
gene products [48,53,108,109,122-124].
There are two main apoptotic pathways: the intrinsic
(mitochondrial) pathway and the extrinsic (death recep-
tor) pathway. The intrinsic pathway involves p53 func-
tioning as a transcription factor to upregulate the
expression of Bax (Figure 4). Bax is a pro-apoptotic pro-
tein that antagonizes Bcl-2, an anti-apoptotic protein
that is present in the mitochondrial membrane [125].
When the Bax/Bcl-2 ratio is increased, the protective
effect of Bcl-2 on the mitochondrial membrane is dis-
rupted and permeability increases, allowing cytochrome
c to leak into the cytosol. Cytochrome c binds to Apaf-1
(apoptotic protease activating factor-1) to form an apop-
tosome complex, which inititates the caspase cascade via
Figure 3 Cell cycle regulation by Rb and p53 tumor suppressor
proteins. A) Inactivation of Rb and p53 proteins occurs by
phosphorylation for the progression of the cell cycle from the G1 to
the S phase. Kinase function of CDK4 is activated by cyclin D1 and
inactivated by p16 proteins. Cyclin E and p21 control the activation
and inactivation of CDK2, respectively. Ubiquitination of p53 takes
place by complexing with MDM2 that is blocked by p14ARF (ARF,
alternative reading frame). B) Inactivation of p16 by deletion,
methylation, or mutation and/or by amplified expression of cyclin
D1 leads to increased phosphorylation of Rb resulting in the
activation of E2F mediated transcription. However, increased
expression of p16 and reduced expression of cyclin D1 results in
hypophosphorylated Rb binding to E2F transcription factor leading
to the inactivation of transcription.
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matic destruction of cytoplasmic proteins and DNA
[126]. Curcumin has been shown to selectively induce
apoptosis in tumor cells at the G2 phase via upregula-
tion of p53 expression and initiation of the mitochon-
drial apoptotic pathway via increased Bax expression
and cytochrome c release [125-129].
Curcumin also has a stimulatory effect on the extrin-
sic apoptotic pathway, which is triggered by the binding
of “death activators” such as TNF-a, and Fas Ligand to
their corresponding cell surface receptors. Activation of
these receptors results in activation of caspase-8 via the
receptor-attached FADD adapter molecule and initiation
of the caspase cascade [130,131]. Curcumin has been
shown to increase the levels of Fas and FADD and
induce apoptosis in mouse-rat retinal ganglion cells
[131]. A study in melanoma demonstrated that curcu-
min led to apoptosis by promoting aggregation of Fas
receptors and by increasing levels of caspase-8 and -3
without altering the level of caspase-9 (unique to the
intrinsic pathway) [132]. In addition, curcumin’ss u p -
pression of the NF-B mediated cell survival pathway is
also important in the compound’s pro-apoptotic effect
[132-134].
Effects on Autophagic Cell Death
Autophagy is a catabolic process in which cells break
down their own components via engulfment in vacuoles
and degradation through the lysosomal system (Figure
5). The hallmark of autophagy is thus the formation of
these so-called “autophagosomes”, double layered
vacuoles which contain cytoplasmic proteins and orga-
nelles targeted for degradation upon fusion with the
lysosome [135]. Autophagy is a housekeeping process by
which cells may dispose of old or damaged cytoplasmic
organelles and proteins, and also serves an adaptive
function under conditions of nutrient stress by allowing
cells to recycle endogenous biosynthetic substrates such
as amino acids.
133 In addition to promoting cell survival
and function, autophagy is also a method by which cells
may undergo programmed cell death [136]. Autophagy
is considered Type II programmed cell death (apoptosis
is type I and necrosis is type III) and, thus has come
under interest as a potential process that may be
exploited in the development of anti-cancer
chemotherapeutics.
T h ep o s s i b l er o l e so fa u t o p h agy in carcinogenesis as
well as tumor regression in response to therapy are still
being elucidated, with seemingly conflicting studies sug-
gesting that induction of autophagy enhances cell death
in certain tumor types while mediating chemotherapeu-
tic resistance in others. On one hand, there is evidence
that autophagy may be employed by cancer cells to facil-
itate growth under the stressful metabolic conditions
commonly encountered in the tumor microenvironment
(such as hypoxia and decreased availability of glucose
and other nutrients due to poor vascularization)
[137-139]. In addition, the induction of autophagy as an
adaptive response mediating resistance to chemotherapy
Figure 4 Programmed cell death type I: Apoptosis: In response
to cellular damage, activation of p53 results in increased
expression of Bax and antagonism of the anti-apoptotic
protein Bcl-2. As a result, mitochondrial membrane permeability
increases and cytochrome C is released into the cytosol.
Cytochrome C binds Apaf-1 to form an apoptosome complex
leading to activation of caspase-9 and initiation of the caspase
cascade and resultant cell death.
Figure 5 Programmed cell death type II: Autophagy is a
catabolic process by which cells degrade their own
components via the lysosomal system. In response to cellular or
nutrient stress, double-layered autophagosomes containing
cytoplasmic proteins and organelles are formed following
envelopment by a membrane derived from the endoplasmic
reticulum. Upon fusion with lysosomes, the contents of these
autophagolysosomes are degraded. Autophagy is important as a
housekeeping function to promote cell survival and may also
function as a pathway of programmed cell death.
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malignant gliomas, lymphoma, breast, lung and hepato-
celluar carcinomas [140-146].
On the other hand, there is genomic evidence that
disruption of autophagy is associated with tumorigen-
esis, as suggested by the mono-allelic deletion of the
autophagy-related gene beclin-1 in a high percentage of
breast and ovarian cancers [147]. Studies in mice have
demonstrated that monoallelic deletion of beclin-1
increases the frequency of spontaneous malignancies
including hepatocellular carcinoma, B cell lymphoma
and lung adenocarcinomas in beclin-1 +/- mice, suggest-
ing beclin-1 as a haploinsufficent tumor suppressor gene
[148]. In addition it was found that monoallelic deletion
of beclin-1 resulted in increased cellular proliferation,
decreased autophagy as measured by expression of the
autophagosome membrane protein LC3, and accelerated
the development of hepatitis B-induced premalignant
lesions [149]. Conversely, transfection of beclin-1 into
MCF-7 breast cancer cells (which express a very low
baseline level of the protein) inhibited the cellular prolif-
eration and tumorigenicity in a nude mouse xenograft
model [147].
While autophagy appears to play a role in mediating
chemoresistance in certain cancers as described above,
there is also data supporting that autophagy may also
induce non-apoptotic cell death in response to che-
motherapy. In human (MCF-7) estrogen-receptor posi-
tive breast cancer, both tamoxifen and paclitaxel were
found to induce autophagic cell death in cell culture
[150,151]. Arsenic trioxide was found to induce autop-
hagic cell death in malignant glioma, leukemia and
fibrosarcoma cells, and in leukemia this effect was
accompanied by up-regulation of beclin-1 [152-154].
The small molecule tyrosine kinase inhibitor imatinib
has been shown to induce cellular autophagy, an effect
that may sensitize drug-resistant Kaposi sarcoma cells
[155,156]. Interestingly, imatinib’s induction of autop-
hagy seems to decrease its effectiveness in chronic mye-
logenous leukemia (CML) and blocking of autophagy
lead to increased apoptotic cell death [142]. Studies
done in malignant glioma cells have also yielded varying
results; while autophagy induced by arsenic trioxide
resulted in increased cell death, treatment with temolo-
zamide and etoposide led to an increase in ATP that
exerted a protective effect [152,157]. Likewise, there is
controversy regarding the effect of autophagy induction
on radiation sensitivity. Studies in breast cancer have
suggested that vitamin D-dependant radiosensitization is
mediated through autophagy, while autophagy has
demonstrated both radiosensitizing and dampening
effects in malignant gliomas [158-160].
Curcumin has been shown to be an inducer of autop-
hagic cell death in chronic myelogenous leukemia,
esophageal cancer and malignant glioma cells [161-163].
In malignant glioma cells, curcumin induced G2/M cell
cycle arrest and non-apoptotic autophagic death. This
effect was mediated through curcumin’s inhibition of
the Akt/mTOR/p70S6 kinase pathway and inhibition of
the ERK1/2 pathway, which are both involved in the
regulation of autophagy induced by nutrient stress. In
addition, these effects were confirmed via activation of
the Akt/mTOR/p70S6 pathway which decreased curcu-
min-induced autophagic cell death as well as activation
of the ERK1/2 pathway, which resulted in inhibition of
autophagy and induction of apoptosis [163,164]. While
the current data on autophagy and cancer is far from
providing a consensus, it is evident that regulation of
this process may play an important role in tumorigen-
esis and response to therapy thus making pharmacologic
modulators of autophagy attractive candidates for
further study.
Effects on Angiogenesis and Metastasis
The stimulation of new blood vessel growth is an essential
step for tumor growth and metastasis in order to provide
for the metabolic needs of rapidly proliferating malignant
cells. Angiogenesis is regulated by a variety of pro-angio-
genic genes and signaling molecules including vascular
endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF), epidermal growth factor (EGF), platelet-
derived growth factors, hypoxia-inducible factors, angio-
poetin-1 and 2, and matrix metalloproteinases [165]. The
role of angiogenesis in tumor growth has been targeted by
newer chemotherapeutic agents such as bevacizumab, an
anti-VEGF monoclonal antibody that is FDA approved for
metastatic forms of various cancers including colon, non-
small cell lung, HER2-negative breast cancer and renal cell
carcinoma. In addition to bevacizumab, sorafenib and
sunitinib are novel small-molecule inhibitors of multiple
receptor tyrosine kinase (RTK) pathways involved in signal
transduction from angiogenic receptors such as VEGFR
and PDGF-R that are approved for renal cell carcinoma as
well as hepatocellular carcinoma and gastrointestinal stro-
mal tumor, respectively [166]. Curcumin has demon-
strated an anti-angiogenic effect in vivo in xenograft
models of various tumors including glioblastoma, hepato-
celluar carcinoma, prostate and ovarian carcinomas
[134,167-169]. Curcumin has been shown to regulate a
variety of pro-angiogenic growth factors, enzymes and
transcription factors including bFGF, VEGF, angiopoetin-1
and 2, COX-2, matrix metalloproteinase-9 (MMP-9), AP-1
and NF-B [170-172]. Curcumin has also been shown to
inhibit the angiogenic response to FGF-2 stimulation in
mouse endothelial cells and decrease the expression of
MMP-9, an enzyme involved in tissue remodeling that is
important for the growth of new blood vessels [171]. In
addition, curcumin treatment decreased the levels of the
Wilken et al. Molecular Cancer 2011, 10:12
http://www.molecular-cancer.com/content/10/1/12
Page 8 of 19angiogenic biomarkers COX-2 and VEGF in hepatocelluar
carcinoma cells, and resulted in a reduction in tumor neo-
capillary density compared to the untreated cells [172].
In addition to its inhibitory effects on angiogenesis,
curcumin has also been demonstrated to affect a num-
ber of cellular adhesion molecules involved in the pro-
cesses of tumor growth and metastasis. A study of
curcumin in metastatic melanoma demonstrated a dose
dependant reduction in binding to extracellular matrix
proteins, decreased expression of alpha5beta1 and alpha
(v)beta3 integrin receptors and increased expression of
various anti-metastatic proteins including tissue inhibi-
tor metalloproteinase (TIMP-2), nonmetastatic gene 23
(Nm23) and E-cadherin [173]. E-cadherin expression is
important in maintaining the integrity of intercellular
adhesion though binding to various catenins (including
b-catenin), and loss of E-cadherin is associated with an
increased tendency for tumor metastasis [174]. Anti-
metastatic effects of curcumin have also been demon-
strated in the MDA-MB-231 breast cancer cell line,
resulting in decreased expression of matrix metallopro-
teinases, ICAM-1 and chemokine receptor 4 (CXCR4)
and suppressed cell migration and invasion [175]. In
addition, curcumin was shown to decrease the ability of
paclitaxel-resistant breast cancer cells to form lung
metastases via suppression of various anti-apoptotic pro-
teins (including XIAP, Bcl-2 and IAP1 and 2), prolifera-
tive (COX-2, c-myc and cyclin D1), and metastatic
proteins (MMP-9, VEGF and ICAM-1) [176]. As many
pro-angiogenic and pro-metastatic genes are regulated by
NF-B (including COX-2, VEGF, ICAM-1 and MMP-9
among others), curcumin’s suppressive effect on NF-B
activation likely plays a key role in mediating the com-
pound’s anti-angiogenic and anti-tumorigenic effects.
Therapeutic Activity of Curcumin in Head and Neck
Squamous Cell Carcinoma
Curcumin has been studied in various in vitro and vivo
models of head and neck squamous cell carcinoma with
promising results. An overview of current literature sup-
porting the spice’s utility in the treatment of head and
neck cancer including as a chemopreventive agent, as
well as future directions for study is presented below.
In Vitro Studies
Studies of curcumin in various head and neck cancer
cell lines have demonstrated decreased cell growth and
survival, concomitant with the compound’se f f e c t so n
molecular pathways involved in cellular proliferation.
Expression of constitutively active NF-Ba n dI Kh a s
been observed in multiple oral squamous cell carcinoma
cell lines, and curcumin treatment was shown to sup-
press growth and survival of these cell lines via inhibi-
tion of NF-B activation [43]. Signal-transducer-and-
activator-of-transcription-3 (STAT3) is a signaling pro-
tein observed to be overexpressed in multiple head and
neck cancers, and curcumin was shown to suppress the
IL-6 mediated phosphorylation of STAT3 as well as
inhibiting nuclear localization [177]. In another study,
Chakravarti et al [178] demonstrated that curcumin sup-
pressed the growth of immortalized oral mucosal epithe-
lial cells and squamous cell carcinoma cells
(UMSCC22B and SCC4) while having minimal effect on
normal oral epithelial cells. Curcumin was shown to
reduce the efficiency of the eIF4F translational complex
of these immortalized cells via suppression of phosphor-
ylation of 4E-BP1, eIF4G, eIF4B and Mnk1, as well as a
reduction in the total levels of eIF4E and Mnk1. In SAS
oral cancer cells, curcumin induced the promoter activ-
ity of insulin-like growth factor binding protein-5
(IGFBP-5) and CCAAT/enhancer-binding protein alpha
(C/EBPalpha), proteins involved in the suppression of
head and neck cancers. The inhibitory effects of curcu-
min on IGFBP-5 and C/EBP-alpha were mediated via
p38 activation, and resulted in decreased in vivo tumori-
genesis in a mouse xenograft model [179].
Our laboratory has studied the effects of curcumin in
several head and neck squamous cell carcinoma cell
lines: CCL23 (laryngeal), CAL27, UM-SCC14A and UM-
SCC1 (oral) [48,53,180]. The growth suppressive effect
was shown to be mainly mediated via the effects of cur-
c u m i no nt h eN F - B pathway. Curcumin was shown to
decrease the expression of NF-B and also inhibited its
nuclear localization; this observation was supported by a
concomitant decrease in phospho-IB-a expression [46].
In addition, the expression levels of multiple NF-B
regulated gene products (including cyclin D1, MMP-9,
COX-2, Bcl-2, Bcl-xL, Il-6, IL-8, Mcl-1L and Mcl-1S)
were reduced [48,53].
It has been demonstrated that the curcumin-induced
suppression of the NF-B pathway in head and neck
cancer cells is due to inhibition of IK( i n h i b i t o rk a p p a
B kinase), thus blocking the phosphorylation of IB-a
and resulting in NF-B sequestration in the cytoplasm.
We have shown dose-dependent suppression of IL-6
and IL-8 following curcumin treatment in CCL23,
CAL27, UM-SCC1 and UM-SCC14A cell lines via inhi-
bition of IK activity [178]. Furthermore, the curcumin-
induced inhibition of IK was found to take place via an
AKT-independent mechanism [53]. The data on curcu-
min’s effect on the AKT pathway is varying; while it has
been shown to act independently of AKT in HNSCC as
well as melanoma, curcumin suppresses the AKT path-
way in other tumors such as malignant gliomas and
pancreatic cancer [96,163,181]. AKT (another kinase of
transcription, also known as protein kinase B) is a pro-
tein kinase involved in signal transduction from onco-
genes and growth factors. The AKT signaling cascade is
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which NF-B may be activated [182]. As discussed ear-
lier, EGFR is overexpressed in many head and neck can-
cers and molecular therapies targeting the EGFR/AKT
signaling cascade (such as cetuximab) have been shown
to increase the therapeutic efficacy of standard plati-
num-based chemotherapy [16,17]. The finding that cur-
cumin suppresses NF-B independently of the AKT
pathway in HNSCC is of clinical significance, as it acts
via a different mechanism than cetuximab and the two
agents could potentially be used in combination for
treating head and neck cancers.
In vivo studies
Curcumin has demonstrated in vivo growth suppressive
effects on head and neck squamous cell carcinoma
using nude mouse xenograft models. The lipophilic nat-
ure of curcumin and relative insolubility in aqueous
solutions, combined with short half life and low bioa-
vailability following oral administration has presented a
significant challenge in developing an effective delivery
system for its use as a chemotherapeutic agent [183]. In
an effort to overcome this obstacle, various strategies
are being tried including the use of piperine as an adju-
vant agent to slow curcumin breakdown as well as the
development of liposomal, phospholipid and nanoparti-
culated formulations of the compound to enable intrave-
nous administration [183]. Liposomal formulations of
curcumin have been studied in various cancers including
pancreatic, colorectal and prostate [184-186].
Intravenous liposomal curcumin has been studied by
our laboratory in mouse xenograft tumors of the oral
cancer cell lines CAL27 and UM-SCC-1, and was found
to be both nontoxic as well as effective at suppressing
tumor growth. Xenograft mouse tumors were stratified
into groups receiving no treatment, treatment with
empty liposomes or treatment with liposome encapsu-
lated curcumin and a statistically significant growth sup-
pressive effect was observed in the liposomal curcumin
group [53]. The presence of curcumin in mouse serum
and liver was confirmed using liquid chromatography-
mass spectrophotometry, demonstrating increased sys-
temic absorption of liposomal curcumin relative to a
DMSO-suspension of curcumin. Immunohistochemistry
of the tumor samples revealed decreased expression of
NF-B in the liposomal curcumin-treated tumors rela-
tive to both the liposomal control and untreated groups,
while the staining intensity of pAKT did not show a sig-
nificant difference among the three treatment groups,
further supporting the in vitro findings that curcumin’s
growth suppressive effects are related to the suppression
of NF-B in an AKT-independent manner [53].
A recent study by Clark et al [187] has shown chemo-
preventive effects of curcumin in mouse xenograft
models of oral squamous cell carcinoma. These authors
have demonstrated an inhibitory effect on tumor growth
following treatment of the mice with an oral curcumin
solution both prior to inoculation of SCC40 tongue
squamous cell carcinoma cells as well as when curcumin
was initiated after tumor formation. In addition, curcu-
min oral solution was studied in a mouse model of oral
carcinogenesis in which the tobacco derivative 4-nitro-
quinolone-1-oxide was painted inside the animal’s
mouths several times weekly, with or without concur-
rent oral curcumin solution. In the mice receiving con-
current curcumin, tumor-free and overall survival times
were significantly increased. Here, the effects of cucu-
min on carcinogenesis suppression were found to be
mediated via inhibition of the AKT/mTOR pathway fol-
lowing analysis of treated and untreated tumor cell
extracts. Finally, curcumin was found to decrease migra-
tion and invasion of malignant oral squamous cells via a
downregulation in MMP-9 expression.
Curcumin as an adjuvant therapy
While studies of curcumin as a single agent in the treat-
ment of head and neck cancer have shown promising
results, there is significant interest in potentially using
the compound as an adjuvant agent in combination with
standard platinum-based chemotherapy for the treatment
of head and neck tumors. Data from our laboratory in
both CAL27 and UMSCC-1 cell lines demonstrated an
increased growth suppressive effect in cells treated with a
combination of liposomal curcumin and cisplatin, both
in vitro as well as in mouse xenograft tumor models
[188]. While treatment with either curcumin or cisplatin
in vitro resulted in cell death, a combination of curcumin
and suboptimal concentrations of cisplatin demonstrated
a significant growth suppressive effect compared to treat-
ment with either agent alone. Curcumin’s suppressive
effect was again shown to derive from the inhibition of
cytoplasmic and nuclear IK, leading to inhibition of NF-
B activity. There was no effect on pAKT, supporting an
AKT-independent mechanism for NF-B inhibition. Cis-
platin treatment led to cellular senescence, an effect
mediated through increased expression of p16 and p53
[7]. Differing mechanisms of curcumin and cisplatin sug-
gest potential for the clinical use of subtherapeutic doses
of cisplatin in combination with curcumin to accomplish
effective suppression of tumor growth while minimizing
cisplatin’s toxic side effects.
In addition to the potential synergistic effect of curcu-
min with platinum based chemotherapy, the spice may
also have potential utility as an enhancer of radiation
therapy. A recent study by Khafif et al [189] compared
the effects of curcumin and single-dose radiation alone
and in combination in the HNSCC cell lines SCC-1,
SCC-9, A431 and KB. In vitro growth suppression with
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cell lines, and the combination of both therapies
resulted in an additive growth suppressive effect. Curcu-
min was found to arrest carcinoma cells in the G2/M
phase of the cell cycle, in which cells are more susceptible
to the cytotoxic effects of radiotherapy. In addition, curcu-
min was shown to decrease COX-2 expression and inhibit
EGFR phosphorylation in SCC-1 cells. In vivo experiments
using orthotopic mouse models of SCC-1 tumors also sup-
ported the additive effects of curcumin and radiation ther-
apy. While curcumin has exhibited varying effects on
radiation sensitivity in different cancer cell types, its effect
as a radiosensitizer has been supported in several other
tumors in addition to HNSCC including prostate, colorec-
tal and ovarian cancers [190-193].
Future Directions of Study for Curcumin in HNSCC
As discussed in this review, curcumin has demonstrated
powerful anti-cancer effects in a variety of malignancies
via its effects on a host of biological pathways involved
in tumorigenesis and cellular growth. Continuing inves-
tigation into the molecular pathways affected by curcu-
min is indicated to further define the effects of the
compound on growth signaling pathways, apoptotic and
non-apoptotic cell death, oncogene and tumor suppres-
sor regulation. Translating this abundance of molecular
data into eventual clinical applications is a paramount
goal of future research. In head and neck cancers, a pro-
mising area of study centers around the use of curcumin
to treat platinum-refractory tumors, which are asso-
ciated with a poorer prognosis and have a tendency for
disease recurrence. Some work has been done in the
area of characterizing putative ‘cancer stem cells’ in a
variety of tumor types including HNSCC, breast, color-
ectal and prostate cancers [194-197]. Cancer stem cells
are not true multipotent stem cells, but are a sub-popu-
lation of highly tumorigenic cells that are theorized to
contribute to chemoresistance and recurrence [198].
CD44 is a cell surface marker that has been shown to
be highly expressed in putative head and neck cancer
stem cells [196-200]. Our laboratory has demonstrated a
population of CD44
High putative stem cells within the
UM-SCC1 cell line that possess increased tumorigeni-
city, growth rate and resistance to cisplatin treatment
relative to CD44
Low cells [201]. Investigating the growth
suppressive properties of curcumin in these highly
tumorigenic cells could be an initial study in quantifying
the utility of the compound in chemotherapy-resistant
head and neck cancers, and may have applications in
other types of chemoresistant malignancies as well. The
solubility of curcumin in an intravenous delivery system
is a major consideration in formulating the compound
as a suitable chemotherapeutic agent. While our labora-
tory and others have shown increased therapeutic
efficacy of liposomal curcumin, it is possible that other
delivery systems may yield superior bioavailability and
therapeutic results.
Other Biologic Therapies Currently Under Investigation in
HNSCC
In addition to curcumin, multiple other biologically tar-
geted agents are currently being studied in head and
neck cancer. As previously mentioned EGFR is overex-
pressed in many head and neck cancers and therefore
represents a promising potential therapeutic target. The
anti-EGFR monoclonal antibody cetuximab is approved
both in combination with radiotherapy as well as a sin-
g l ea g e n tf o rp l a t i n u m - r e s i s t a n tH N S C C ,b u ti sa l s o
being investigated in combination with standard che-
motherapeutic regimens. A Phase I/II trial of cetuximab
with 5-FU and either carboplatin or cisplatin showed
increased survival without a significantly increased toxi-
city relative to the standard chemotherapy regimen
(Table 1) [202]. However, acquired resistance to EGFR
inhibition by cetuximab has emerged as a therapeutic
challenge [203]. A variant of EFGR (EGFRvIII) that
results in constitutive activation of the downstream Ras/
Raf/MAPK, STAT3 and PI3/AKT/mTOR pathways has
been observed in HNSCC that is not responsive to
EGFR inhibition [204]. In addition to targeting the
extracellular EGF receptor, tyrosine kinase inhibitors
(erlotinib, gefitinib, lapatinib) that block intracellular
EGFR phosphorylation and inhibit downstream signal
transduction are also being studied in HNSCC. A Phase
II study of erlotinib in patients with recurrent or meta-
static head and neck cancer showed an increase in dis-
ease stabilization (Table 2) [205]. A Phase III trial of
gefitinib alone compared to methotrexate monotherapy
in recurrent HNSCC failed to show a significant survival
increase, but a more recent study of gefitinib added to
concurrent chemoradiation showed a favorable response
that correlated to the number of EGFR copies in the
various tumors [206,207].
Targeted therapies against the vascular endothelial
growth factor receptor (VEGF) are also being evaluated
in HNSCC. The anti-VEGF monoclonal antibody bevaci-
zumab in combination with paclitaxel showed increased
anti-tumor effects in mouse xenograft tumor models of
HNSCC compared to either agent alone [208]. A combi-
nation of bevacizumab and erlotinib was also studied in a
Phase I/II clinical trial in recurrent or metastatic HNSCC
and demonstrated a response rate of 15%, which was sig-
nificantly increased compared to prior studies of erlotinib
(5%) or single agent anti-angiogenic therapies (4%) [209].
Constitutive activation of the PI3-K/Akt/mTOR path-
way has been observed in head and neck cancer and is
associated with resistance of such tumors to radiation
and chemotherapy [210]. As such employing rapamycin
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olimus may prove useful in the treatment of refractory
head and neck cancers. The experimental mTOR inhibi-
tor CCI-779 has been studied as a single agent in mouse
models of HNSCC minimal residual disease and demon-
strated a significant increase in the tumor-free rate
between the treatment and control groups (50% vs. 4%
respectively) as well as a reduction in tumor volume in
the CCI-779 group [211]. Analysis of the radiosensitiz-
ing effect of CCI-779 in mouse xenograft models of
both cisplatin sensitive (FaDu) and resistant (SCC40)
head and neck squamous cell carcinoma showed
increased survival relative to radiotherapy alone. In addi-
tion, the antitumor effects of CCI-779 plus radiotherapy
were superior when compared to conventional chemora-
diotherapy with cisplatin in both the FaDu and SCC40
xenograft tumors [212].
In addition to the major pathways discussed above,
several other novel biologic agents are under investiga-
tion in head and neck cancer that merit brief mention.
Sorafenib is a multikinase inhibitor targeting the MAP
kinase pathway (RAF/MEK/ERK) as well as several other
receptor tyrosine kinases including VEGFR, PDGFR,
FLT3, Ret and c-kit [213]. It is currently FDA approved
for treatment of advanced primary renal cell carcinoma
and hepatocellular carcinoma. A Phase II trial of sorafe-
nib in chemotherapy-naïve persistent or recurrent
HNSCC showed a relatively poor response rate of 2%,
but progression-free and overall survival compared favor-
ably with other single agent Phase II trials [214]. Peme-
trexed is a folate antimetabolite currently FDA approved
in combination with cisplatin for malignant mesothe-
lioma. A Phase I study of pemetrexed in combination
with cisplatin for HNSCC showed no enhancement in
Table 2 Current molecular pathway based therapies in head and neck cancer
Agent Molecular target Phase/model of investigation in HNSCC Reference
Erlotinib/
Gefitinib/
Lapatinib
Anti-EGFR receptor kinase Erlotinib: Phase II study in refractory/metastatic
HNSCC
Gefatinib: PhaseIII vs methotraxate in recurrent
HNSCC
[205-207]
Bevacizumab Anti-VEGF monoclonal antibody Mouse xenograft models: in combination with
paclitaxel
Phase I/II trial of bevacizumab and erlotinib in
recurrent/metastatic HNSCC
[208]
Rapamycin
derivatives
(Everolimus,
Deferolimus
Temserolimus)
Inhibition of PI3K/AKT/mTOR pathway Mouse xenograft model: Single agent CCI-779 in
minimal residual disease
Mouse xenograft model: CCI-779 in combination
with radiotherapy
[210-212]
Sorafenib Multikinase inhibitor targeting MAP kinase, VEGFR, PDGFR
FLT3, Ret, c-kit
Phase II: in chemotherapy-naïve persistent/recurrent
HNSCC
[213,214]
Pemetrexed Folate antimetabolite Phase I: in combination with cisplatin in HNSCC
Phase II: Pemetrexed plus gemcitabine in recurrent/
metastatic HNSCC
[215,216]
Bortezomib Proteosome inhibitor Phase I: Bortezomib with re-irradiation in HNSCC
Phase II: Bortezomib with docetaxel in recurrent/
metastatic HNSCC in vitro: Synergistic anti-tumor
effect of Bortezomib and cisplatin in HNSCC cell
lines
[217-219]
Curcumin Inhibition of NF-kB activation, Suppression of interleukins, Cell
cycle inhibition, Suppression of VEGF and other angionegic
factors, Up-regulation of cellular adhesion molecules, inhibition
of STAT 3
in vitro: Growth suppression of HNSCC cell lines with
decreased NF-kB activation
[48,53]
in vitro: Suppression of IL-6 and IL-8 expression in
HNSCC
[180]
in vitro: Growth suppression of immortalized
epithelial cells
[178,187]
Mouse xenograft: Suppression of CAL 27 cell line
tumors
[48,53]
Mouse model: Inhibition of oral carcinogenesis [178,187]
in vitro and mouse model: Synergistic anti-tumor
effect of Curcumin and cisplatin in CAL 27 and UM-
SCC1 cell lines
[188]
in vitro and mouse model: Radiosensitization of SCC-
1, SCC-9, A431, and KB HNSCC cell lines with
curcumin
[189,190]
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pharmacokinetics [215]. A Phase II trial of pemetrexed
plus gemcitabine in recurrent or metastatic HNSCC
demonstrated a partial response rate of 16% and was
well-tolerated [216]. Bortezomib is a proteosome inhibi-
tor that is FDA approved for the treatment of multiple
myeloma and mantle cell lymphoma. The cytoplasmic to
nuclear translocation and activation of NF-Bi sap r o -
teosome-dependant process, and bortezomib has been
shown to inhibit nuclear activation of the RelA and NF-
B1 subunits in HNSCC [217]. In addition bortezomib
has been found to induce apoptosis in HNSCC cells via
up-regulation of the pro-apoptotic proteins Bik and Bim,
and the combination of bortezomib and cisplatin resulted
in a synergistic tumoricidal effect in HNSCC [218]. A
Phase II trial of bortezomib in combination with doce-
taxel in recurrent and/or metastatic HNSCC was well-
tolerated and demonstrated better therapeutic response
in tumors expressing lower levels of NF-Ba s s o c i a t e d
genes [219].
Conclusions
The need for alternative and less toxic therapies for
head and neck squamous cell carcinoma is clear. Multi-
ple molecular pathways such as NF-B activation, EGFR
and PI3/AKT/mTOR signaling, STAT3 expression, the
MAP kinase cascade and VEGF-mediated angiogenesis
have been shown to be deregulated in HNSCC and
represent potential therapeutic targets. While some pro-
mising results from such targeted therapies have been
obtained, the complexity of interaction between these
signaling pathways may contribute to the limited clinical
response seen with the use of single-agent biologic
therapies. As a natural product, curcumin is both non-
toxic as well as diversified in its inhibitory effects on a
multitude of pathways involved in carcinogenesis and
tumor formation. While the compound alone has shown
some anti-tumor effects in HNSCC, curcumin’sl a c ko f
systemic toxicity and broad-reaching mechanism of
action may make it best suited as an adjuvant therapy
for head and neck cancers that are resistant to currently
available therapies.
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